This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Scientists build harness for powerful radiation cancer therapy

05 February 2013

Researchers have demonstrated the ability to harness powerful radioactive particles and direct them toward small tumours while doing negligible damage to healthy organs and tissues.

The nanoparticle that Robertson's research team created is multi-layered. At the core lies the element, actinium, surrounded by four layers of material

Typically, when radiation treatment is recommended for cancer patients, doctors are able to choose from several radio-pharmaceuticals that use low-energy beta particles. However, for years, scientists have been studying how to use much more energetic alpha particles in cancer treatments. The challenges to using alpha particles, which are more than 7,000 times heavier than beta particles, include confining them in a designated location inside the body while preventing radiation from affecting healthy organs and tissues.

J. David Robertson, director of research at the MU Research Reactor says there have had some successes using alpha particles recently, but nothing that can battle different cancers. "For example, a current study using radium-223 chloride, which emits alpha particles, has been fast-tracked by the US Food and Drug Administration because it has been shown to be effective in treating bone cancer," he explains. "However, it only works for bone cancer because the element, radium, is attracted to the bone and stays there. We believe we have found a solution that will allow us to target alpha particles to other cancer sites in the body in an effective manner."

Robertson and researchers from Oak Ridge National Laboratory and the School of Medicine at the University of Tennessee in Knoxville used the element actinium - a known alpha emitter. As it decays, actinium creates three additional elements that produce alpha particles. Due to the strength of these particles though, keeping the elements in place at cancer sites was not possible, until Robertson and Mark McLaughlin, MU doctoral student and co-author on the study, designed a gold-plated nanoparticle that serves as a holding cell for the elements, keeping them in place at the cancer site.

Robertson's nanoparticle is a layered device. At the core is the original element, actinium. Robertson's team then added four layers of material and then coated the nanoparticle with gold. This made the nanoparticle strong enough to hold the actinium – and the other alpha emitters that are eventually created – long enough for any alpha particles to destroy nearby cancer cells.

"Holding these alpha emitters in place is a technical challenge that researchers have been trying to overcome for 15 years," Robertson said. "With our nanoparticle design, we are able to keep more than 80 percent of the element inside the nanoparticle 24 hours after it is created."

Scientists at the University of Missouri, Oak Ridge, and the University of Tennessee have created a gold nanoparticle that can harness the power of alpha emitters for radioactive therapy

While alpha particles are extremely powerful, they don't travel very far, so when the nanoparticles get close to cancer cells, the alpha particles move out and destroy the cell much more effectively than current radiation therapy options, Robertson said.

"Previously, basic research had established that scientists can attach antibodies onto gold nanoparticles that help drive the nanoparticles to the tumour sites in the body," Robertson said. "Without that groundbreaking work, we would not have been able to put this puzzle together."

The early-stage results of this research are promising. If additional studies are successful within the next few years, MU officials will request authority from the US federal government to begin human drug development.

The study is being published this week in PLOS ONE, an international, peer-reviewed and open-access publication.

A video is available for viewing on the MU website.


Print this page | E-mail this page